Polymer particles

US9938367B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9938367-B2
Application numberUS-201715630048-A
CountryUS
Kind codeB2
Filing dateJun 22, 2017
Priority dateSep 19, 2013
Publication dateApr 10, 2018
Grant dateApr 10, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

First claim

Opening claim text (preview).

We claim: 1. An embolic system including: a delivery device; and an embolic solution including polymer particles, wherein the polymer particles include: an acrylate, acrylamide, methacrylamide, methyl methacrylate, or a combination thereof, and a crosslinker, wherein the polymer particles have a spherical diameter between about 40 μm and about 1,200 μm. 2. The embolic system of claim 1 , wherein the polymer particles are susceptible to degradation through hydrolysis or enzymatic action, and wherein the degradation provides less than about 10% of the polymer particles intact after about 5 days. 3. The embolic system of claim 1 , wherein the spherical diameter is between about 75 μm and about 1,200 μm. 4. The embolic system of claim 1 , wherein the crosslinker includes at least two functional groups. 5. The embolic system of claim 1 , wherein the crosslinker includes at least one linkage susceptible to degradation through hydrolysis or enzymatic action. 6. The embolic system of claim 1 , wherein the crosslinker is bis-glycidyl amino alcohol, wherein a, b, c, d, e, and f are each independently 1-20. 7. The embolic system of claim 5 , wherein the at least one linkage is an ester, a thioester, a carbonate, a peptide cleavable by matrix metalloproteinases, a peptide cleavable by matrix collagenases, a peptide cleavable by matrix elastases, a peptide cleavable by matrix cathepsins, or a combination thereof. 8. The embolic system of claim 1 , including a second crosslinker including a second linkage selected from an ester, a thioester, a carbonate, a peptide cleavable by matrix metalloproteinases, a peptide cleavable by matrix collagenases, a peptide cleavable by matrix elastases, and a peptide cleavable by matrix cathepsins. 9. The embolic system of claim 1 , wherein the crosslinker is bis-glycidyl amino alcohol or bi-functionalized methacryloyl-Ala-Pro-Gly-Leu-AEE-methacrylate. 10. The embolic system of claim 1 , wherein the delivery device is a catheter. 11. The embolic system of claim 1 , wherein the delivery device is a microcatheter. 12. The embolic system of claim 1 , wherein the delivery device is a needle. 13. The embolic system of claim 1 , wherein the delivery device and the embolic solution are sterilized. 14. The embolic system of claim 1 , wherein the embolic solution includes a monomer including an ionizable functional group. 15. The embolic system of claim 14 , wherein the ionizable functional group is basic or acidic. 16. The embolic system of claim 1 , wherein the embolic solution includes a radiopaque contrast agent. 17. The embolic system of claim 1 , wherein the embolic solution includes a dye. 18. The embolic system of claim 1 , wherein the embolic solution is provided in a vial. 19. The embolic system of claim 1 , wherein the embolic solution is provided in a syringe. 20. The embolic system of claim 1 , wherein the polymer particles have a circularity greater than about 0.9.

Assignees

Inventors

Classifications

  • substituted imides comprising other heteroatoms · CPC title

  • Acrylamide; Methacrylamide · CPC title

  • Nitrogen-containing compounds {(C08K5/0091 takes precedence)} · CPC title

  • Biodegradable · CPC title

  • Particulate matter [e.g., sphere, flake, etc.] · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9938367B2 cover?
Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.
Who is the assignee on this patent?
Terumo Corp
What technology area does this patent fall under?
Primary CPC classification C08J3/12. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).